Trial reportInfection and immunity2004
Strain-specific humoral response to a polymorphic malaria vaccine.
Trial report in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Vaccines for preventing malaria (blood-stage).The Cochrane database of systematic reviews · 2006Pooled it
- Allelic frequency ofMalariaWorld journal · 2025Article
- Naturally acquired IgG responses toFrontiers in immunology · 2024Article
- In silico characterisation of putative Plasmodium falciparum vaccine candidates in African malaria populations.Scientific reports · 2021Article
- T-follicular helper cells in malaria infection and roles in antibody induction.Oxford open immunology · 2021Review
- Host-Malaria Parasite Interactions and Impacts on Mutual Evolution.Frontiers in cellular and infection microbiology · 2020Review
- High-resolution micro-epidemiology of parasite spatial and temporal dynamics in a high malaria transmission setting in Kenya.Nature communications · 2019Article
- Immunogenicity analysis of genetically conserved segments in Plasmodium ovale merozoite surface protein-8.Parasites & vectors · 2019Article
- Disordered epitopes as peptide vaccines.Peptide science (Hoboken, N.J.) · 2018Review
- Higher Complexity of Infection and Genetic Diversity ofThe American journal of tropical medicine and hygiene · 2017Article
- Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria.International journal for parasitology · 2017Review
- Regulating STING in health and disease.Journal of inflammation (London, England) · 2017Review
- Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.Scientific reports · 2016Article
- Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens.BMC microbiology · 2015Article
- Structural basis for epitope masking and strain specificity of a conserved epitope in an intrinsically disordered malaria vaccine candidate.Scientific reports · 2015Article
- Genetic polymorphism of merozoite surface protein-1 in Plasmodium falciparum isolates from patients with mild to severe malaria in Libreville, Gabon.Parasite (Paris, France) · 2015Article
- Conformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2.PloS one · 2015Article
- Molecular Evolution of PvMSP3α Block II in Plasmodium vivax from Diverse Geographic Origins.PloS one · 2015Article
- Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains.Malaria journal · 2014Article
- Low genetic diversity and functional constraint in loci encoding Plasmodium vivax P12 and P38 proteins in the Colombian population.Malaria journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
Abstract
The 3D7 form of the merozoite surface protein 2 (MSP2) of Plasmodium falciparum was one of three subunits of the malaria vaccine Combination B that were tested in a phase I/IIb double-blind randomized placebo-controlled trial, which was undertaken with 120 Papua New Guinean children of 5 to 9 years of age. Because only one variant of the highly polymorphic MSP2 was used for vaccination, we examined whether the elicited response was directed against conserved or strain-specific epitopes. Postvaccination (week 12) titers of antibody against recombinantly expressed individual domains of MSP2 were measured by enzyme-linked immunosorbent assay and compared to baseline values. We found that vaccination with the 3D7 form of MSP2 induced a significant strain-specific humoral response directed against the repetitive and semiconserved family-specific part. The conserved N- and C-terminal domains were not immunogenic. Titers of antibody against the alternate FC27 family-specific domain showed a tendency to increase in vaccinated children, but there was no increase in antibodies against FC27-type 32-mer repeats. These results indicate that vaccination with one MSP2 variant mainly induced a strain-specific response, which can explain the selective effect of vaccination with combination B on the genotypes of breakthrough parasites. These findings support the inclusion of both family-specific domains (3D7 and FC27) in an improved vaccine formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.